

| COMPANY PROFILE FORM | |
|----------------------|--|
| Name | ELDRUG S.A. |
| Short profile | <p>ELDRUG S.A. is a spin off Biotechnology Company established in January 2007 and based on research results and expertise obtained at the University of Patras. Laboratory Discoveries led to Novel Biochemical Methods, Medicinal Products and Potential Drugs, in the Treatment of Hypertension / Cardiovascular Diseases and Multiple Sclerosis, named ELSARTAN and ELMYELIN.</p> <p>Elsartan has attracted the interest of the biggest Pharmaceutical Company in Greece VIANEX, investing €1.000.000 matched by an equivalent almost amount by Ministry of Development. Elsartan has passed successfully Pre-clinical Potency Evaluation in a number of Bioassays as Pressure Suppressor in several Animal Models (rats, rabbits, Intravenous, Subcutaneous, Transdermal, Preliminary Toxicity). An IND Application File is under preparation to be submitted for Approval by EMEA (European Medicine Agency) for Clinical Trial Phase I.</p> <p>ELDRUG, with a personel of 15 Medicinal Chemistry experts, is collaborating with Biomedical groups of Excellence. The Scientific Advisory Board (SAB) is comprised by World Leading Scientists (Jean-Marie Lehn, Nobel in Chemistry 1987, Kyriakos Nicolaou, Aris Patrinos, Haralambos Gavras, Michael Maragoudakis, Dionisios Cokinos, Vasso Apostolopoulos).</p> <p>ELDRUG possesses High Tech Equipment and Facilities in Analysis, Identification, Synthesis (HPLC, HPLC-MS, Preparative HPLC, Reactor).</p> <p>ELDRUG is the result of Combination: Excellent Research - Innovation -Technology which led to Novel Products and Enterprise.</p> |





| | |
|--|---|
| <p>Research and Development Activity:</p> | <p>The company has developed the following patented products:</p> <ul style="list-style-type: none"> • Elsartan: Potential Antihypertensive, transdermally delivered, towards clinical Phase I trial preparation and submission of IND • Elmyelin: Potential Drug in the Immunotherapy of Multiple Sclerosis towards clinical Phase I trial preparation and submission of IND • ELGonad: Induction of Ovulation in Fish Hatcheries (Sea Bass, Sea Bream, Grey Mullet) <p>A) Angiotensin and Elsartan in the treatment of Hypertension and Cardiovascular Diseases (Owned by ELDRUG)</p> <p>Elsartan is an Antihypertensive with further properties, in particular to lower Blood Pressure transdermally, besides oral, intravenous and subcutaneous action. The structure of Elsartan is based on Imidazole and Dialkylation.</p> <p>PRECLINICAL PHARMACOLOGICAL PROPERTIES OF ELSARTAN (BV6)</p> <ol style="list-style-type: none"> 1. cost effective (Two step synthesis), 2. transdermal delivery (lipophilic), 3. similar or lower toxicity (versus Losartan), 4. same activity at lower concentration (IC50), 5. long duration <p>B) Elmyelin in the Immunotherapy of Multiple Sclerosis (Owned by Researchers)</p> <p>Elmyelin is a cocktail of Myelin Epitopes and potential drug in the Immunotherapy of disease. Novel substances based in the Protein Myelin implicated in M.S. Disease have been designed, synthesized and evaluated with important results in Animal Models of the disease.</p> <p>PROPERTIES OF ELMYELIN</p> <ol style="list-style-type: none"> 1. They suppress Experimental Autoimmune Encephalomyelitis (EAE) in acute and chronic assays using rat animal models 2. They suppress the proliferation of a CD4 T-cell line raised from multiple sclerosis patients 3. They score a favourable in vitro TH2/TH1 cytokine ratio in peripheral blood mononuclear cell cultures derived from multiple sclerosis patients, inducing therapeutic IL-10 selectively with simultaneous reduction of inflammatory INF-D 4. They bind to HLA-DR4, first to be reported for cyclic MBP peptides 5. Cyclic peptides were found to be more stable to lysosomal enzymes and Cathepsin B, D, and H, compared to their linear counterparts 6. Conjugation of 91-96 MBP83-99 mutant peptides, linear or cyclic with reduced Mannan divert Inflammatory Th1 to Therapeutic Th2. <p>C) Gonadotropin- Releasing Hormone (GnRH) Analogues for the Induction of Ovulation in Fish Hatcheries</p> <p>ElGonad is a Gonadotropine Releasing Hormone Analog which has been designed and synthesized in the company's laboratories for ovulation in fish. GnRH and its analogues are currently used in human IVF clinics and in fish farming, the latter representing a multimillion dollar market which is expanding rapidly worldwide. The technology has been successfully applied in Fish Hatcheries in Greece in Sea Bass, Sea Bream and Mullet.</p> <p>In particular, in Sea Bass, injection with GnRH Peptide Analogue, [Tyr(OMe)5, D-Ser6, Aze9-NHEt]-GnRH, stimulated ovulation in vivo (over 400.000 - 500.000 eggs per fish) which was well above that stimulated by natural hormone GnRH (100.000 eggs per fish).</p> |
| <p>Partner search with activity in the following research areas:</p> | <p>Eldrug is in close collaboration with its main shareholder VIANEX and with various CROs (Contract Research Organizations).</p> <p>The company is interested in collaborating with research organizations with expertise in transdermal delivery of drugs. It is also interested in collaborating with experts in toxicological evaluation of drugs in animal models.</p> |
| <p>CONTACT</p> | |
| <p>Name of Contact person:</p> | <p>Prof I. Matsoukas, Dr Maragoudakis</p> |
| <p>e-mail:</p> | <p>eldrug@eldrug.gr, praxi@help-forward.gr</p> |
| <p>Web Site:</p> | <p>www.eldrug.gr</p> |